Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma - Summary - MDSpire

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

  • By

  • Laura B. Oswald

  • Xiaoyin Li

  • Lisa M. Gudenkauf

  • Gabe De Avila

  • David Scheiber-Camoretti

  • Brent J. Small

  • Brian D. Gonzalez

  • Aasha I. Hoogland

  • Oanh Nguyen

  • Yvelise Rodriguez

  • Sylvia L. Crowder

  • Nathan H. Parker

  • Tiffany L. Carson

  • Christine E. Vinci

  • Rachid C. Baz

  • Kenneth H. Shain

  • Brandon Blue

  • Ariel Grajales-Cruz

  • Kristy Matte

  • Brandon Kale

  • David Kaldas

  • Fabiana Perna

  • Melissa Alsina

  • Ciara L. Freeman

  • Omar Castaneda Puglianini

  • Taiga Nishihori

  • Hien Liu

  • Frederick L. Locke

  • Heather S. L. Jim

  • Lauren C. Peres

  • Doris K. Hansen

  • May 11, 2026

  • 0 min

Share

Objective:

To assess and compare patient-reported outcome (PRO) trajectories among patients with relapsed/refractory multiple myeloma receiving idecabtagene vicleucel (ide-cel) versus ciltacabtagene autoleucel (cilta-cel) CAR-T therapy.

Key Findings:
  • Ide-cel recipients were older than cilta-cel recipients (median age 73 vs. 64 years, p < 0.001).
  • Many PROs worsened pre-D7 and improved post-D7, including overall HRQOL and physical well-being (p-values < 0.05).
  • Differences in social well-being pre-D7 (p = 0.01) and cognitive function post-D7 (p = 0.001) were observed between treatment groups.
Interpretation:

Patients with RRMM receiving CAR-T therapy exhibited similar PRO trajectories regardless of CAR-T type, with initial worsening or stability followed by significant improvement post-treatment.

Limitations:
  • The study was limited to a single cancer center, which may affect generalizability.
  • The sample size may limit the robustness of findings regarding differences between treatment groups.
Conclusion:

Future studies should explore differences in PRO trajectories beyond D90 post-treatment and further investigate social well-being and cognitive function outcomes.

Original Source(s)

Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma

  • by Laura B. Oswald, Xiaoyin Li, Lisa M. Gudenkauf, Gabe De Avila, David Scheiber-Camoretti, Brent J. Small, Brian D. Gonzalez, Aasha I. Hoogland, Oanh Nguyen, Yvelise Rodriguez, Sylvia L. Crowder, Nathan H. Parker, Tiffany L. Carson, Christine E. Vinci, Rachid C. Baz, Kenneth H. Shain, Brandon Blue, Ariel Grajales-Cruz, Kristy Matte, Brandon Kale, David Kaldas, Fabiana Perna, Melissa Alsina, Ciara L. Freeman, Omar Castaneda Puglianini, Taiga Nishihori, Hien Liu, Frederick L. Locke, Heather S. L. Jim, Lauren C. Peres, Doris K. Hansen

  • May 11, 2026

Related Content

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report